APLT News and Press, Applied Therapeutics Inc. From 09/19/23

2023-09-19 13:01:28 ET Gainers: Connexa Sports Technologies ( CNXA ) +170% . Davis Commodities Limited Ordinary Shares ( DTCK ) +83% . Maplebear ( CART ) +40% . Avinger ( AVGR ) +40% . Rackspace Technology ( RXT ) +37% . Elut...

Applied Therapeutics, Inc. (NASDAQ: APLT) is one of today's top gainers. The company's shares are currently up 22.76% on the day to $2.43. Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabeti...

2023-09-06 12:53:35 ET Gainers: NeuBase Therapeutics ( NBSE ) +124% . Palisade Bio ( PALI ) +113% . Power REIT ( PW ) +45% . AeroVironment ( AVAV ) +26% . Theratechnologies ( THTX ) +27% . iCoreConnect ( ICCT ) +20% ....

2023-09-06 10:00:10 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...

2023-09-06 09:17:41 ET More on Applied Therapeutics Seeking Alpha’s Quant Rating on Applied Therapeutics Historical earnings data for Applied Therapeutics Financial information for Applied Therapeutics Applied Therapeutics: Buy For Upcoming Pre-NDA Mee...

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced successful completion of...

2023-08-17 04:28:21 ET Summary Applied Therapeutics is a micro-cap with low cash balance, but has major upcoming catalysts (pre-NDA meeting for galactosemia and phase 3 results in diabetic cardiomyopathy) and a huge upside potential. Despite missing the primary endpoint in galacto...

2023-08-10 12:25:36 ET Applied Therapeutics press release ( NASDAQ: APLT ): Q2 GAAP EPS of -$0.37. Cash and cash equivalents and short-term investments totaled $35.6 million as of June 30, 2023, compared with $30.6 million at December 31, 2022. For further details se...

Regulatory progress for govorestat (AT-007) for the treatment of Classic Galactosemia, with potential NDA submission based on discussions with the FDA as well as EMA Marketing Authorization Application planned in Fall 2023 Phase 3 INSPIRE Trial of govorestat in Sorbitol Dehydrogenase (S...

2023-08-07 03:55:11 ET Summary Applied Therapeutics has experienced regular positive trial updates, frequent delays in NDA submission, and multiple dilutive stock offerings. The company's lead candidate, AT-007, showed a strong reduction in plasma galactitol but did not meet the F...